About Triphendiol:

Triphendiol (NV-196) is an investigational drug in the Marshall Edwards,Inc., oncology drug pipeline, currently being developed as anorally-delivered chemosensitizing agent, intended for use in conjunctionwith standard chemotoxic anti-cancer drugs for the treatment of late stagepancreatic cancer, cholangiocarcinoma, and melanoma. Triphendiol wasgranted orphan drug status by the U.S. Food and Drug Administration forpancreatic cancer and cholangiocarcinoma in January 2008 and for treatmentof stage IIb-IV malignant melanoma in February 2008.

Triphendiol is broadly cytostatic and cytotoxic against most forms of humancancer cells in vitro, and has been shown to cause cell cycle arrest (orstop cells increasing in number) and to induce apoptosis (or initiateprogrammed cell death) in various cancer cell lines. Biological studiessuggest a mechanism of cytotoxicity that involves mitochondrialdepolarization and downregulation of XIAP. It exhibits high selectivity,little effect on non-tumor cells and no observable toxicity in animals attherapeutically effective doses. In human studies conducted in Australia,no adverse events or side effects have been reported when administered tovolunteers.

About Marshall Edwards, Inc:

Marshall Edwards, Inc. (NASDAQ: MSHL) is a specialist oncology companyfocused on the clinical development of novel anti-cancer therapeutics.These derive from a flavonoid technology platform, which has generated anumber of novel compounds characterized by broad ranging activity against arange of cancer cell types with few side effects. The combination ofanti-tumor cell activity and low toxicity is believed to be a result of theability of these compounds to target an enzyme present in the cell membraneof cancer cells, thereby inhibiting the production of pro-survival proteinswithin the cell. Marshall Edwards, Inc. has licensed rights from NovogenLimited (ASX: NRT) (NASDAQ: NVGN) to bring three oncology drugs --phenoxodiol, triphendiol and NV-143 -- to market globally. The Company'slead investigational drug, phenoxodiol, is in a Phase III multinationalmulti-centered clinical trial for patients with recurrent ovarian cancer.More information on the trial can be found at http://www.OVATUREtrial.com.

Marshall Edwards, Inc. is majority owned by Novogen, an Australianbiotechnology company that is specializing in the development oftherapeutics based on a flavonoid technology platform. Novogen isdeveloping a range of therapeutics across the fields of oncology,cardiovascular disease and inflammatory diseases. More information onphenoxodiol and on the Novogen group of companies can be found atwww.marshalledwardsinc.com and www.novogen.com.

Under U.S. law, a new drug cannot be marketed until it has beeninvestigated in clinical trials and approved by the FDA as being safe andeffective for the intended use. Statements included in this press releasethat are not historical in nature are "forward-looking statements" withinthe meaning of the "safe harbor" provisions of the Private SecuritiesLitigation Reform Act of 1995. You should be aware that our actual resultscould differ materially from those contained in the forward-lookingstatements, which are based on management's current expectations and aresubject to a number of risks and uncertainties, including, but not limitedto, our failure to successfully commercialize our product candidates; costsand delays in the development and/or FDA approval, or the failure to obtainsuch approval, of our product candidates; uncertainties in clinical trialresults; our inability to maintain or enter into, and the risks resultingfrom our dependence upon, collaboration or contractual arrangementsnecessary for the development, manufacture, commercialization, marketing,sales and distribution of any products; competitive factors; our inabilityto protect our patents or proprietary rights and obtain necessary rights tothird party patents and intellectual property to operate our business; ourinability to operate our business without infringing the patents andproprietary rights of others; general economic conditions; the failure ofany products to gain market acceptance; our inability to obtain anyadditional required financing; technological changes; governmentregulation; changes in industry practice; and one-time events. We do notintend to update any of these factors or to publicly announce the resultsof any revisions to these forward-looking statements.

Contact:Warren Lancaster+1-203-966-2556 (USA)Email ContactAlan Husband+61 2 9878 0088 (Australia)Email Contact